Anti-Fibrinolytic Drugs - United Arab Emirates

The revenue generated in the Anti-Fibrinolytic Drugs market in the United Arab Emirates is projected to reach US$31.43m in 2024.
It is expected that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 5.90%, leading to a market volume of US$41.86m by 2029.
In comparison to other countries worldwide, United States is anticipated to generate the highest revenue of US$9.86bn in 2024.
The United Arab Emirates is witnessing a growing demand for anti-fibrinolytic drugs due to an aging population and an increase in cardiovascular diseases.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in United Arab Emirates is experiencing steady growth in recent years.

Customer preferences: The demand for Anti-Fibrinolytic Drugs is driven by the increasing prevalence of bleeding disorders and the growing aging population. Patients with bleeding disorders require timely and effective treatment to prevent serious complications, and Anti-Fibrinolytic Drugs are an important part of their treatment regimen. Additionally, the increasing awareness of the benefits of Anti-Fibrinolytic Drugs among healthcare professionals and patients is also contributing to the growth of the market.

Trends in the market: The Anti-Fibrinolytic Drugs market in United Arab Emirates is witnessing an increasing trend towards the development of new and innovative drugs. Pharmaceutical companies are investing heavily in research and development to introduce new drugs that are more effective and have fewer side effects. Additionally, the market is also witnessing a trend towards the use of combination therapy, where Anti-Fibrinolytic Drugs are used in combination with other drugs to enhance their effectiveness.

Local special circumstances: One of the key drivers of the Anti-Fibrinolytic Drugs market in United Arab Emirates is the high prevalence of bleeding disorders in the region. The Middle East and North Africa (MENA) region has one of the highest incidences of bleeding disorders in the world, and the demand for Anti-Fibrinolytic Drugs is expected to remain strong in the coming years. Additionally, the increasing investment in healthcare infrastructure and the growing healthcare spending in the region are also contributing to the growth of the market.

Underlying macroeconomic factors: The Anti-Fibrinolytic Drugs market in United Arab Emirates is also influenced by several macroeconomic factors. The country's growing population and the increasing prevalence of chronic diseases are driving the demand for healthcare services, including Anti-Fibrinolytic Drugs. Additionally, the government's initiatives to promote medical tourism and the increasing number of medical tourists in the country are also contributing to the growth of the market. Finally, the favorable regulatory environment and the increasing investment in research and development by pharmaceutical companies are also supporting the growth of the Anti-Fibrinolytic Drugs market in United Arab Emirates.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.